Clinical Trials Recruiting Men with Advanced Prostate Cancer in California
For men with metastatic castration-resistant prostate cancer (mCRPC) residing in Southern California outside of San Diego, several clinical trials are currently seeking participants. These studies aim to explore new treatment options and improve patient outcomes. Below is an overview of notable trials, including their locations and links to more information:
1. Combination Therapy with ZEN003694 and Enzalutamide
Study Focus: This Phase 2b study evaluates the efficacy of combining ZEN003694, a bromodomain inhibitor, with enzalutamide, a standard therapy, in patients with mCRPC.
Location: University of California, San Francisco (UCSF), San Francisco, CA.
2. PSMA-Directed Targeted Alpha Therapy with FPI-2265
Study Focus: This Phase 2 trial investigates the safety and efficacy of FPI-2265, a targeted alpha therapy directed at Prostate-Specific Membrane Antigen (PSMA), in treating mCRPC.
Location: Hoag Memorial Hospital Presbyterian, Newport Beach, CA.
Details: PSMA-Directed Targeted Alpha Therapy with FPI-2265 for mCRPC (TATCIST)
3. Re-Treatment with 177Lu-PSMA-617
Study Focus: This Phase 2 trial assesses the effectiveness of re-treating mCRPC patients with 177Lu-PSMA-617, a radioactive drug targeting PSMA, after an initial favorable response.
Location: University of California, Los Angeles (UCLA) / Jonsson Comprehensive Cancer Center, Los Angeles, CA.
Details: Re-Treatment with 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
4. Study of JANX007 in mCRPC Patients (ENGAGER-PSMA-01)
Study Focus: This Phase 1 trial evaluates the safety and preliminary efficacy of JANX007, a PSMA-targeted therapy, in adults with mCRPC.
Location: Los Angeles, CA, and other locations.
Details: Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Participation and Eligibility
Men aged 18 and older diagnosed with mCRPC may be eligible to participate in these trials. Each study has specific inclusion and exclusion criteria, so it's essential to consult with healthcare providers to determine suitability.
How to Get Involved
For more detailed information on these trials, including eligibility requirements and enrollment procedures, please consult with your oncologist or visit the provided links. Participating in a clinical trial not only provides access to cutting-edge therapies but also contributes to advancing medical research in prostate cancer treatment.
Staying informed about ongoing research and emerging treatments is crucial for those affected by mCRPC. We encourage our support group members to discuss these opportunities with their healthcare teams and consider participation in clinical trials as a viable option in their treatment journey.
Comments
Post a Comment